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Abstract 
Purpose: Neoadjuvant chemotherapy (NCT) using anthracyclines and taxanes is a standard treatment for locally 
advanced breast cancer. Efficacy of NCT is however variable among patients and predictive markers are expected to 
guide the selection of patients who will benefit from NCT. A promising approach stand with polymorphisms located 
in genes encoding drug transporters, drug metabolizing enzymes and target genes which can affect drug efficacy. 
Our study investigated the potential of 37 polymorphisms to predict response to NCT in breast cancer.
Methods: 118 women with breast adenocarcinoma were treated with FEC100 and taxotere. Genotyping was per‑
formed on germline DNA using the BioMark platform (Fluidigm). Pathological complete response (pCR) according to 
Sataloff criteria was correlated to clinical characteristics and genotypes using univariate and multivariate analyses.
Results: 25 patients (21.2%) reached complete pathologic response. pCR rate is increased in SBRIII (p = 0.009), ER 
negative (p = 0.005) and triple negative (p = 0.006) tumors. pCR rate is significantly increased for patients carrying 
at least one variant allele for BRCA1, ERCC1 or SLCO1B3, and for patients homozygous for CYP1B1. The combination of 
ERCC1 and CYP1B1 polymorphisms is a potential predictor of NCT response in breast cancer (pCR rate reached 50 vs 
21.2% for unselected patients), and particularly in ER + breast cancer subtype where pCR rate reached 41.2 vs 13.5% 
for unselected patients.
Conclusions: This study is the first to report ERCC1, BRCA1 and SLCO1B3 as markers of response to NCT in breast 
cancer. ERCC1/CYP1B1 combination might be of particular interest to predict response to NCT in breast cancer and 
particularly to help NCT indication for ER+ breast tumors.
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Background
Neoadjuvant chemotherapy (NCT) improves clini-
cal outcome as patients whose tumors respond to NCT 
have superior disease-free and overall survival than 
patients whose tumors do not (Rastogi et al. 2008). Thus, 
predicting the chance of response before starting NCT 
is crucial to identify patients who will benefit from NCT 
and help to select for the appropriate drugs. Up to now, 
several markers such as tumor size, histological type, 
hormone receptor status, and HER2 expression are used 
to predict efficiency of NCT. However, despite the con-
sideration of these tumor characteristics, heterogeneity 
in therapy efficacy still subsists and accurate predictive 
markers for NCT are lacking.
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Genetic variations such as single nucleotide poly-
morphisms (SNPs) are present across individuals and 
might affect pharmacokinetics and pharmacodynam-
ics of drugs. SNPs in genes encoding drug transport-
ers, drug metabolizing enzymes and target genes can 
directly affect the drug uptake, its activation and its 
excretion, accessibility of the target and also related 
pathways that can potentiate its action. Conse-
quently, SNPs might lead to therapeutic failures and/
or adverse drug reactions. Currently, UDP glucurono-
syltransferase 1A1polymorphism UGT1A1*28 is used 
to predict toxicity of irinotecan in colorectal cancer 
treatment. Genotyping allows individuals homozy-
gous for the variant allele of UGT1A1 to be treated 
with reduced doses of irinotecan and to avoid severe 
toxicity.
The aim of our study was to identify SNPs as predic-
tive markers for breast cancer NCT. In our institution, 
breast cancer women treated with NCT receive 5-FU, 
cyclophosphamide, anthracyclines and/or taxanes. 
Thus, we selected SNPs previously reported in the lit-
erature to be associated with response to these chem-
otherapeutic agents. Thirty-seven SNPs, located in 
genes encoding influx and efflux transporters such as 
SLCO1B3, MDR1 and ABCC4, in genes belonging to 
drug metabolism (CYP1B1, CYP2B6, CYP3A4, MTHFR 
and GSTP1…) and also in genes of DNA repair pathway 
such as XRCC1, ERCC1, BRCA1 and p53 (Additional file 




191 women with histological proven breast adenocar-
cinoma were enrolled in the study between November 
2007 and January 2012 (ClinicalTrials.gov identifier: 
NCT00959556). Patients were treated with anthracy-
clines and/or taxanes based NCT in our institution 
(Centre Oscar Lambret, Lille, France). Among them, 
118 received FEC100-Taxotere, 46 patients with HER2+ 
tumors were treated with FEC100-Taxotere-Herceptin, 
16 patients were treated with FEC100 and 11 patients 
received diverse chemotherapy regimens.
Patient characteristics are summarized in Table  1 
for the two main groups. Median age at diagnosis was 
46.5  years for patients treated with FEC100-taxotere 
and 45.5  years for patients treated with FEC100-tax-
otere-herceptin. The median size of the tumors was 
30  mm for patients treated with FEC100-taxotere and 
30.5  mm for patients treated with FEC100-taxotere-
herceptin. The histoprognostic grading was established 
according to Scarff Bloom and Richardson modified by 
Elston and Ellis (1998). FEC100-Taxotere was mostly 
administrated during 6 cycles (84.7%) and the major-
ity of patients (82.2%) received 3 cycles of FEC100 
followed by 3 cycles of Taxotere. The median number 
Table 1 Characteristics of patients treated with FEC100-
taxotere and FEC100-taxotere-herceptin
CR complete response, PR partial response, SD stable disease, PD progressive dis-
ease, NA not applicable, pCR pathological complete response.
a Percentages of evaluable patients (except for NA: percentage of all patients).
b Estrogen receptor or progesterone receptor positive.
c Estrogen receptor and progesterone receptor negative.
d IHC3+ or IHC2+/FISH+ or CISH+.
FEC100-taxotere FEC100-taxotere-
herceptin
N = 118 %a N = 46 %a
Tumor type
Ductal carcinoma 106 89.9 44 95.6
Lobular carcinoma 7 5.9 1 2.2
Other 5 4.2 1 2.2
Tumor size
T0‑T1 5 4.3 1 2.3
T2 60 51.7 21 48.8
T3 24 20.7 11 25.6
T4 27 23.3 10 23.3
NA 2 1.7 3 6.5
Histoprognostic grade
SBRI 7 6.7 1 2.5
SBRII 54 51.9 19 47.5
SBRIII 43 41.3 20 50
NA 14 11.9 6 13.1
Nodal status
Positive 63 54.3 30 65.2
Negative 53 45.7 16 34.8
NA 2 1.7 0 0
Hormone receptor status
Positiveb 77 66.3 23 50.0
Negativec 39 33.6 23 50.0
NA 2 1.7 0 0.0
HER-2 status
Positived 5 4.7 46 100.0
Negative 102 95.3 0 0.0
NA 11 9.3 0 0.0
Clinical response
CR 11 12.2 7 21.9
PR 62 68.9 23 71.9
SD 15 16.7 2 6.3
PD 2 2.2 0 0.0
NA 28 23.7 14 30.4
pCR
Yes 25 21.2 18 40.0
No 93 78.8 27 60.0
NA 0 0.0 1 2.2
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of treatment cycles of Herceptin per patient was 18 
(3–18).
Our study only focused on patients treated with 
FEC100-Taxotere (n =  118), in order to identify poten-
tial predictive polymorphisms in a homogeneous group 
according to treatment.
Clinical response assessment
Clinical evaluation of response to therapy was assessed 
by measuring tumor size (physical examination and 
ultrasonography) before NCT, and after 3 and 6 cycles. 
Change in tumor size was determined by comparing the 
tumor size before and after NCT according to RECIST 
guidelines, version 1.1 (Eisenhauer et al. 2009).
Pathological response assessment
Tumor response was assessed by a pathologist and 
graded according Sataloff et  al. (1995). Pathologi-
cal tumor response was used as the gold standard to 
evaluate treatment response. On the basis of patients’ 
pathological response in primary breast site and/or in 
the lymph nodes, patients were designated having a 
pCR when surgical samples showed total or near-total 
effect and absence of nodal involvement (TA and NA 
or NB).
Hormone receptors and HER2 assessment
Immunohistochemistry (IHC) was used for evaluation of 
oestrogen receptors (ER) (1D5 Dako clone, then SP1 Ven-
tana clone) and progesterone receptors (PR) (1A6 Dako 
clone, then PR88 Biogenex clone); to be positive, more 
than 10% of the tumor nucleus cells had to be stained. 
Evaluation of HER2 was performed with IHC (CB11 
Biogenex clone, then HER 485 Dako clone); only tumors 
classified 3+ were considered positive. All tumors HER2 
2+ with IHC were tested by FISH. Triple negative tumors 
were defined as ER and PR negative and HER2 negative 
by immune histochemistry (IHC) or by FISH in case of 
HER2 2+.
DNA extraction
Genomic DNA was extracted from EDTA-treated 
blood samples (300 µl) using the MagNA Pure Compact 
instrument (Roche Diagnostics, Meylan, France) and 
the MagNA Pure Compact Nucleic Acid Isolation Kit 
according to the manufacturer’s instructions.
Genotyping
SNP genotyping was assessed using allelic discrimina-
tion with SNPType assays ordered from Fluidigm. When 
SNPType assays were not available, TaqMan assays 
(Life Technologies) were used instead. Because DNA 
concentration available was below supplier recommen-
dation, a Specific Target Amplification was performed 
to enrich targeted SNP sequences according to the sup-
plier’s instructions.
Instrumentation and nanofluidic chips
48.48 Dynamic Array used in the present study are nano-
fluidic chips able to analyze 48 samples with 48 SNP 
assays on the BioMark platform (Fluidigm). The BioMark 
system is used to thermal cycle these nanofluidic chips 
and image the data in real time.
SNP genotyping using SNPType assays
3  µL of SNPType ASP1/ASP2 (allele specific primer 1 
and 2) and 8  µL of SNPtype LSP were premixed and 
dilute with 29  µL of DNA suspension buffer to prepare 
SNPType assay mix. Each assay (5  µL) comprised 1  µL 
SNPType assay mix, 2.5µL assay loading reagent 2X (flui-
digm) and 1.5  µL DNA-free water. Each sample (6  µL) 
comprised 3 µL Biotium fast probe master mix 2X (Bio-
tium), 0.3  µL sample loading reagent 20X (fluidigm), 
0.1 µL SNPType reagent 60X (Fluidigm), 0.036 µL ROX 
50X (Invitrogen), 0.064  µL DNA-free water and 2.5µL 
amplified genomic DNA. Each of the assays (4  µL) and 
samples (5  µL) was pipetted into separate inlets in the 
chip. Amplification was carried out under the follow-
ing conditions: 95°C for 5 min, 38 cycles of 95°C for 15 s, 
60°C for 45 s, 72°C for 15 s followed by 30 s at 20°C for 
fluorescence measurement.
SNP genotyping using TaqMan assays
Each assay (5 µL) comprised 2.5 µL assay loading reagent 
2X (fluidigm), 0.25  µL ROX 50X (Invitrogen), 1.25  µL 
SNP Genotyping assay mix 40X (Applied Biosystems) 
and 1 µL DNA-free water. Each sample (6 µL) comprised 
3 µL TaqMan universal PCR master mix 2X (Applied Bio-
systems), 0.3  µL sample loading reagent 20X (fluidigm), 
0.3  U AmpliTaq gold polymerase (Applied Biosystems), 
0.12 µL DNA-free water and 2.52 µL amplified genomic 
DNA. Each of the assays (4 µL) and samples (5 µL) was 
pipetted into separate inlets in the chip. Amplification 
was carried out under the following conditions: 50°C for 
2 min, 98°C for 10 min, 40 cycles of 95°C for 15 s, 60°C 
for 60 s. Fluorescence was measured at each slice.
Software
The data were analyzed using the BioMark SNP Geno-
typing Analysis software version 3.1.2 to obtain genotype. 
Briefly, the software calculates the FAM, VIC or HEX flu-
orescence intensities relative to ROX fluorescence back-
ground, and then automatically classifies the samples into 
three possible genotypes.
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Statistical analysis
Clinical and histopathological characteristics were pre-
sented as frequencies and percentages for categorical 
variables and as medians and range for continuous vari-
ables. Associations between pCR and clinicopathological 
characteristics were assessed using Khi-2 test for quali-
tative variables or Fisher exact test in the case of small 
counts. Associations between pCR and continuous vari-
ables were performed using Wilcoxon Mann–Whitney 
test.
After ensuring that Hardy–Weinberg equilibrium 
was respected, the search of SNP correlated to pCR was 
performed by univariate logistic regression (R SNPas-
soc package). For each SNP, analyses were done consid-
ering genotypes separately or grouped to compare each 
homozygous or heterozygous genotype to other ones 
(only significant results are shown). Univariate analyses 
were repeated on subgroups of the population according 
to ER tumor status.
Multivariate analysis was performed on whole popula-
tion combining significant SNP in a stepwise multivari-
ate logistic regression selecting variables according to the 
Akaike Information Criterion (AIC). The model was vali-
dated internally on 1,000 random samples with replace-
ment on the whole dataset. The percentage of times each 
variable was selected was extracted. Only those variables 
which were selected in >80% of models were retained. 
The final model was adjusted for ER status.
Results of statistical tests were considered significant at 
the 5% level. Analyses were performed using v11.2 Stata 
software (StataCorp. 2009. Stata Statistical Software: 
Release 11. College Station, TX, USA) and v2.15.2 R soft-
ware (R Core Team 2012).
Results
Association between pCR and clinicopathological 
characteristics
25 patients (21.2%, CI 95%: 14.2–29.7%) reached com-
plete pathologic response according to Sataloff crite-
ria. Median age at diagnosis was 46 years for responder 
patients, 47 years for non-responder patients and was not 
significantly correlated to pCR.
The associations between pCR and clinicopathologi-
cal features are summarized in Table  2. No statistically 
significant correlations were observed between pCR and 
tumor size, nodal status or KI67. Patients with higher 
tumor grade were significantly more likely to achieve a 
pCR than those with lower tumor grade (p = 0.009). We 
also observed different pCR rates according to Hormone 
Receptors (HR) status: patients whose tumors were posi-
tive for at least one HR had a pCR rate of 15.6% whereas 
patients who were HR negative had a pCR rate of 33.3% 
(p  =  0.003). Contrary to PR negativity, ER negativity 
is a significant marker of pCR (p =  0.005). pCR rate is 
higher for ER− tumors (35.7%) than for ER+ tumors 
(13.5%; p =  0.005). Tumors with triple negative pheno-
type achieved significantly higher pathologic response 
rate than those with non-triple negative phenotype (40.6 
vs 16.0%, p = 0.006).
Association between pCR and the 37 selected SNPs
Among the 37 SNPs evaluated, genotyping data were 
available for 114 of the 118 patients enrolled in the study. 
The distribution of the genotypes and allelotypes indi-
cated that all frequencies were in Hardy–Weinberg equi-
librium and were consistent with previously reported 
Caucasian populations (data not shown).
Univariate analysis revealed that 4 SNPs are signifi-
cantly associated with pCR (Table 3).
Patients carrying at least one variant allele for BRCA1 
(T), ERCC1 (C) and SLCO1B3 (G) have about a threefold 
higher likelihood to achieve a pCR to NCT than other 
patients. Patients homozygous for CYP1B1 Leu432Val 
showed increased pCR rate compared to heterozygous 
patients (respectively pCR  =  29% and pCR  =  11.1%, 
p = 0.020).
Subsequently, assessment of associations between com-
binations of these SNPs and pCR showed that a model 
containing only ERCC1 and CYP1B1 polymorphisms 
performed as well as more complex models. Stepwise 
logistic regression combining the four significant SNPs 
identified the model containing CYP1B1 and ERCC1 as 
the best: these SNPs were validated respectively in 81.0 
and 80.8% of the models whereas BRCA1 and SLCO1B3 
were selected in 69.2 and 72.3% of the models. The 
ERCC1 CT genotype associated with CYP1B1 CC geno-
type had the highest OR of 8.5 (p = 0.013; Table 4). pCR 
rate reached 50% for patients harboring these genotypes 
whereas the pCR rate is 21.2% in the whole population.
Association between pCR and SNPs considering ER status
In breast cancer, tumor subtypes are associated with dif-
ferent responses to neoadjuvant therapies. For example, 
highly proliferative ER− breast tumors are more sensitive 
to NCT than ER+ breast tumors: pCR rates are respec-
tively 28–32 and 2–10% (von Minckwitz 2013; Colleoni 
et al. 2004; Kaufmann et al. 2012).
As pCR can be achieved only in a minority of patients 
with ER+ breast tumors, it is of particular interest to 
identify patients who can avoid neoadjuvant chemo-
therapy or who are candidates for a very high probability 
of pCR after chemotherapy. Therefore, among the four 
SNPs previously described as significantly associated 
to pCR, we searched for potential predictive marker for 
ER+ breast tumors. pCR is significantly increased for 
patients carrying variant alleles of BRCA1, SLCO1B3 
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and CYP1B1 (Table  5, genotyping data obtained for 71 
patients).
Considering patients with ER− tumors, only ERCC1 
(Asn118Asn) is significantly associated with response to 
NCT (Table 6, genotyping data obtained for 41 patients). 
Patients carrying at least one variant allele for ERCC1 (C) 
have a fourfold higher likelihood to achieve a pCR after 
NCT than patients with other genotypes.
Moreover, combined ERCC1-CT and CYP1B1-CC 
genotypes remain significant when adjusted on ER status 
Table 2 Association between clinicopathological features and pCR in FEC-Taxotere treated group (N = 118)
NA not applicable, pCR pathological complete response.
* Khi-2 test.
†  Fisher exact test.
‡  Wilcoxon Mann–Whitney test.
a Percentages of evaluable patients.
b Estrogen receptor or progesterone receptor positive.
c Estrogen receptor and progesterone receptor negative.
Total pCR (N = 25) No pCR (N = 93) P value
N = 118 n %a n %a
Tumor size 
T0‑T1 5 1 20.0 4 80.0
T2 60 16 26.7 44 73.3
T3 24 3 12.5 21 87.5
T4 27 4 14.8 23 85.2 NS†
NA 2 1 1
Histopronostic grade
SBRI–SBRII 61 9 14.8 52 85.2
SBRIII 43 16 37.2 27 62.8 0.009*
NA 14 0 14
Nodal status
Positive 63 12 19.1 51 80.9
Negative 53 12 22.6 41 77.4 NS†
NA 2 1 1
KI67
Positive 42 12 28.6 30 71.4
Negative 6 0 0.0 6 100.0 NS†
NA 70 13 57
Hormone receptor status
RH
  Positiveb 77 12 15.6 65 84.4
  Negativec 39 13 33.3 26 66.7 0.003*
  NA 2 0 2
RE
  Positive 74 10 13.5 64 86.5
  Negative 42 15 35.7 27 64.3 0.005*
  NA 2 0 2
RP
  Positive 57 10 17.5 47 82.5
  Negative 58 15 25.9 43 74.1 NS*
  NA 3 0 3
Triple negative
  Yes 32 13 40.6 19 59.4
  No 75 12 16.0 63 84.0 0.006*
  NA 11 0 11
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(p = 0.005; Table 7). In consequence, pCR rate reached 41.2% 
for patients with ER+ tumors harboring these genotypes 
whereas the pCR rate is only 13.5% for unselected patients 
with ER+ tumors. pCR rate is twice higher for patients with 
ER- tumors harboring combined ERCC1-CT and CYP1B1-
CC genotypes than for unselected patients (80 vs 37.5%).
Discussion
In order to identify breast cancer patients who will ben-
efit from anthracyclines and/or taxanes based NCT, 
we analyzed the relationship between 37 SNPs and the 
response to these chemotherapeutic agents.
First overall, our data confirmed that response to NCT is 
related to clinicopathological features such as histoprognos-
tic tumor grade and hormone receptor status. According to 
previous published data (von Minckwitz 2013), we observed 
that pCR rate is increased in SBRIII and HR negative tumors 
and that ER- tumors respond better to NCT than ER+ 
tumors. Our data also indicated that patients with triple 
negative tumors achieve significantly higher pathologic 
complete response rate than those with non-triple negative 
tumors. Unexpectedly, pCR was not significantly associated 
to KI67 expression in our study. Nevertheless, this obser-
vation may be explained in part by the fact that data were 
missing for more than half of patients.
Secondly, considering the predictive value of the 37 
studied SNPs, we demonstrated using univariate analyses 
that BRCA1 (Pro871Leu) and ERCC1 (Asn118Asn), two 
polymorphisms located in DNA repair genes, and also 
CYP1B1 (Leu432Val) and SLCO1B3 (IVS12-5676), two 
polymorphisms in genes involved in drug metabolism, 
are linked to response to taxanes and anthracyclines. 
Multivariate analysis revealed that ERCC1 (Asn118Asn) 
combined to CYP1B1 (Leu432Val) might be of particular 
Table 3 pCR is related to 4 SNPs (N = 114)
NA not applicable, pCR pathological complete response.
a Percentages of evaluable patients.
Gene SNP Genotype N pCR (N = 25) OR 95% CI P value
rs # wt n %a
BRCA1 rs799917 C CC 44 5 11.4 1
Pro871leu CT‑TT 66 19 28.8 3.15 (1.08–9.2) 0.025
NA 4 1
SLCO1B3 rs11045585 A AA 79 13 16.5 1
IVS12‑5676 AG‑GG 34 12 35.3 2.77 (1.10–6.7) 0.031
NA 1 0
CYP1B1 rs1056836 C CG 45 5 11.1 1 0.020
Leu432Val CC‑GG 69 20 29.0 3.26 (1.12–9.5)
ERCC1 rs11615 T TT 40 4 10.0 1
Asn118Asn CT‑CC 73 21 28.8 3.63 (1.15–11.5) 0.016
NA 1 0
Table 4 pCR is related to combination of CYP1B1 and ERCC1 polymorphisms
Significant results are shown in italic.
pCR pathological complete response.
a  Percentages of evaluable patients.
CYP1B1 (Leu432Val) ERCC1  
(Asn118Asn)
N pCR OR 95% CI P value
n %a
CC TT 19 2 10.5 1 Reference
CC CT 22 11 50.0 8.5 (1.6–46) 0.013
CC CC 6 1 16.7 1.7 (0.13–23) 0.69
CG TT 15 1 6.7 0.61 (0.05–7.4) 0.70
CG CT 20 2 10.0 0.94 (0.12–7.5) 0.96
CG CC 10 2 20.0 2.1 (0.25–18) 0.49
GG TT 6 1 16.7 1.7 (0.13–23) 0.69
GG CT 8 3 37.5 5.1 (0.66–39) 0.12
GG CC 7 2 28.6 3.4 (0.38–31) 0.28
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interest as predictive markers for NCT in breast cancer. 
Indeed, we observed that patients exhibiting ERCC1-CT 
genotype combined to CYP1B1-CC genotype presented a 
doubling of pCR rate compared with unselected patients 
(50 vs 21.2%).
Our results are in agreement with previous published 
data. The BRCA1 variant allele (T) is associated with 
better overall survival and longer progression-free sur-
vival compared to the reference allele in patients with 
advanced gastric cancer treated with taxanes and cispl-
atin (Shim et al. 2010).
Although considered as neutral, the functional signifi-
cance of Pro871Leu (C > T) polymorphism of BRCA1 is 
still unknown. Pro871Leu might affect expression, activ-
ity or interaction of BRCA1 with its partners. As a conse-
quence, Pro871Leu might impair DNA repairing function 
of BRCA1 and might contribute to potentiate efficacy of 
DNA damaging agents.
ERCC1 CC genotype was reported to confer longer 
survival and time to progression in patients with NSCLC 
treated with cisplatin plus docetaxel (Isla et al. 2004). Any 
other study described a link between ERCC1 polymor-
phism and response to taxanes/anthracyclines, probably 
because ERCC1 polymorphism has extensively been stud-
ied in response to platinium compounds, ERCC1 C geno-
type being related to both a better (Isla et al. 2004; Chang 
et  al. 2009; Kalikaki et  al. 2009; Warnecke-Eberz et  al. 
2009; Metzger et al. 2012) and a worse response (Viguier 
et al. 2005; Kamikozuru et al. 2008; Ren et al. 2012). The 
consequence of the silent polymorphism Asn118Asn 
(T  >  C) on ERCC1 transcription and expression is not 
elucidated and remains still conflicting. Gao & co had 
Table 5 BRCA1, SLCO1B3 and CYP1B1 are significantly associated with pCR in ER + tumors (N = 71)
Significant results are shown in italic.
NA not applicable, pCR pathological complete response.
a Percentages of evaluable patients.
Gene SNP Genotype N pCR (N = 10) OR 95% CI P value
rs # wt n %a
BRCA1 rs799917 C CC 26 0 0.0
Pro871Leu CT‑TT 42 9 21.4 0.010
NA 3 1
SLCO1B3 rs11045585 A AA 49 4 8.2 1
IVS12‑5676 AG‑GG 21 6 28.6 4.50 (1.12–18.1) 0.032
NA 1 0
CYP1B1 rs1056836 C CG 26 0 0.0
Leu432Val CC‑GG 45 10 22.2 0.011
ERCC1 rs11615 T TT 22 1 1.5
Asn118Asn CT‑CC 48 9 18.8 0.08
NA 1 0
Table 6 ERCC1 is significantly associated with pCR in ER- tumors (N = 41)
Significant results are shown in italic.
NA not applicable, pCR pathological complete response.
a Percentages of evaluable patients.
Gene SNP Genotype N pCR (N = 15) OR 95% CI P value
rs # wt n %a
BRCA1 rs799917 C CC 17 5 29.4
Pro871leu CT‑TT 23 10 43.5 0.36
NA 1 0
SLCO1B3 rs11045585 A AA 28 9 32.1
IVS12‑5676 AG‑GG 13 6 46.2 0.39
CYP1B1 rs1056836 C CG 18 5 27.8
Leu432Val CC‑GG 23 10 43.5 0.29
ERCC1 rs11615 T TT 17 3 17.6 1
Asn118Asn CT‑CC 24 12 50.0 4.7 (1.06–20) 0.030
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demonstrated no difference in ERCC1 transcription nor 
expression between cells stably expressing ERCC1-T 
allele or ERCC1-C allele (Gao et al. 2011). However, data 
obtained on lymphocytes of prostate cancer patients 
revealed that carriers of CC genotype showed lower 
ERCC1 mRNA levels (Woelfelschneider et al. 2008).
Thus, by decreasing ERCC1 mRNA levels, C genotype 
might decrease ERCC1 mediated DNA repair and might 
contribute to potentiate efficacy of DNA damaging drugs. 
This hypothesis is in agreement with clinical data which 
present that low levels of ERCC1 are favorable for sen-
sitivity to platinium compounds (Li et  al. 2000; Shirota 
et al. 2001; Lord et al. 2002; Wang et al. 2008).
CYP1B1 Val genotype is associated with lower response 
rate, shorter progression-free-survival and decrease 
overall survival in breast and prostate cancer patients 
treated with taxanes based chemotherapy (Marsh et  al. 
2007; Sissung et al. 2008; Pastina et al. 2010). However, in 
our study, only Leu/Val genotype provided the best data 
fit for the SNP Leu432Val. The hypothesis of an over-
dominant model, previously described in bladder cancer 
(Salinas-Sanchez et  al. 2012), might be explained by a 
higher enzyme activity in heterozygous than in homozy-
gous. CYP1B1 binds and sequestrates docetaxel reduc-
ing its available concentration and influencing its activity 
(McFadyen et al. 2001). CYP1B1 also produces oestrogen 
metabolites that limit docetaxel efficacy by inhibition 
of tubulin polymerization (Sissung et  al. 2008). Thus, 
by increasing CYP1B1 mRNA expression and catalytic 
activity (Shimada et al. 1999; Hanna et al. 2000; Li et al. 
2000; Landi et al. 2005), Leu432Val substitution appears 
to modulate response to taxanes.
SLCO1B3 is an influx transporter involved in the uptake 
of a broad range of drug substrates including docetaxel 
(Konig et  al. 2000; Smith et  al. 2005). The functional 
impact of rs11045585 polymorphism is yet unknown. 
However, asian nasopharyngeal cancer patients homozy-
gous for the variant allele had higher area under curve 
and less plasma clearance of docetaxel compared to 
patients carrying at least one reference allele (Chew et al. 
2011). It is to be noted that rs11045585 polymorphism is 
proposed to exert its functional effect by being in hap-
lotypic combination with 3 other polymorphism in the 
SLCO1B3 gene (Chew et al. 2012).
Finally, as pCR is rarely achieved by NCT in ER+ breast 
tumors, we searched if BRCA1 (Pro871Leu), ERCC1 
(Asn118Asn), CYP1B1 (Leu432Val) and SLCO1B3 
(IVS12-5676) could stand for predictive markers of NCT 
for patients with this subtype of tumor. Our results indi-
cated that BRCA1 (Pro871Leu), CYP1B1 (Leu432Val) 
and SLCO1B3 are significantly associated with response 
to NCT in ER+ tumors. ERCC1/CYP1B1 combination 
remains significant for ER+ tumors and might be useful 
to help indication of NCT in this particular type of tumors 
as patients exhibiting ERCC1-CT genotype combined to 
CYP1B1-CC genotype presented a threefold higher pCR 
rate compared with unselected patients: 41.2 vs 13.5%.
Our data also indicated that ERCC1 Asn118Asn might 
be a potential predictive marker for NCT in ER- tumors, 
as pCR is increased to 50% for patients carrying at least 
one variant allele (C).
In conclusion, BRCA1 (Pro871Leu), ERCC1 (Asn118Asn), 
CYP1B1 (Leu432Val), and SLCO1B3 (rs11045585) are asso-
ciated with response to NCT in our cohort of breast cancer 
Table 7 pCR is related to combination of CYP1B1 and ERCC1 polymorphisms when adjusted on ER status
Significant results are shown in italic.
pCR pathological complete response.
a Percentages of evaluable patients.
CYP1B1 (Leu432Val) ERCC1 (Asn118Asn) N pCR OR 95% CI P value
n %a
CC TT 19 2 10.5 1 Reference
CC CT 22 11 50.0 16.1 (2.3–112) 0.005
CC CC 6 1 16.7 2.8 (0.16–47) 0.48
CG TT 15 1 6.7 0.41 (0.03–5.6) 0.51
CG CT 20 2 10.0 0.77 (0.09–6.8) 0.81
CG CC 10 2 20.0 2.4 (0.24–25) 0.45
GG TT 6 1 16.7 0.89 (0.06–13.5) 0.93
GG CT 8 3 37.5 4.4 (0.46–41) 0.20
GG CC 7 2 28.6 3.1 (0.28–34) 0.35
ER− 42 15 1 Reference
ER+ 71 10 0.12 (0.03–0.43) 0.001
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patients. To our knowledge, this study is the first to report 
ERCC1, BRCA1 and SLCO1B3 as markers of taxanes and/or 
anthracyclines response in breast cancer NCT.
Moreover ERCC1/CYPB1 combination appeared to be 
a potential predictive marker to guide NCT indication in 
breast cancer and particularly for ER+ breast tumors.
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